We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.
Glenn Deshields compared the side-effects of the coronavirus vaccine to a “hangover” for 24 hours. Mr Desheilds told Good Morning Britain’s Piers Morgan and Susanna Reid that he would advise everyone to get the vaccine as quickly as they can.
He said regarding his experience of the trial: “I would compare it to a mild hangover from the side effects I had.
“There was an injection side pain that lasted about two or three days.
“The second dose I had a similar response.
“I did take an anti-body test after that second dose and I do have anti-bodies now.
“I have been tested for coronavirus multiple times and have always been negative.”
Mr Morgan asked: “For those that may be wary about having the vaccine what would your message be?”
Mr Deshields replied: “Get it as quick as you can get it.
“This is the only way to end this, a vaccine just being produced does not do us any good.
“Everybody getting vaccinated ends it so I would tell everybody to get it done and as soon as they allow you to get it.”
Ms Reid asked: “The worst that happened to you having been injected with the vaccine was you felt like you had a bit of a hangover?”
Mr Deshileds responded: “Correct, I had a headache and I was fatigued for 24 hours.”
Ms Reid said: “Regarding longer-term side-effects, you haven’t experienced anything negative?”
Holidays: ‘Devastating’ impact of covid on Britons’ holidays laid bare [INSIGHT]
Prince William condemned: Future King sparks anger over cover-up [ANALYSIS]
Christmas lockdown: Italy facing coronavirus disaster [VIDEO]
Mr Deshields added: “Nothing, I am two months after the last dose and I am as good as over, and I don’t have the coronavirus.”
On Monday morning it was announced that pharmaceutical company Pfizer has produced a vaccine that is 90 percent effective.
The Pfizer vaccine results are based on the first interim analysis of Phase 3 of the study.
It evaluated 94 confirmed cases of COVID-19 in trial participants. The study enrolled 43,538 participants.
Source: Read Full Article